Tags

Type your tag names separated by a space and hit enter

Agonist and antagonist effects of 15R-prostaglandin (PG) D2 and 11-methylene-PGD2 on human eosinophils and basophils.
J Pharmacol Exp Ther. 2007 Jan; 320(1):173-9.JP

Abstract

Prostaglandin (PG) D2 acts through both the DP(1) receptor, which is coupled to adenylyl cyclase, and the DP2 receptor (chemoattractant receptor-homologous molecule expressed on Th2 cells), which is present on eosinophils, basophils, and Th2 cells and results in cell activation and migration. The most potent prostanoid DP2 agonist so far reported is 15R-methyl-PGD2, in which the hydroxyl group has the unnatural R configuration. In contrast, the corresponding analog possessing the natural 15S configuration is approximately 75 times less potent. This raised the question of whether the isoprostane 15R-PGD2 might have potent DP2 receptor-mediated biological activity. We therefore chemically synthesized 15R-PGD2 and investigated its biological activity. This compound elicited DP2 receptor-mediated CD11b expression in human basophils and eosinophils and induced actin polymerization and migration in eosinophils with a potency about the same as that of PGD2. In contrast, it had only a weak effect on DP1 receptor-mediated adenylyl cyclase activity in human platelets. We also investigated the effects of modification of the 9-hydroxyl and 11-oxo groups of PGD2. Both PGK2, in which the 9-hydroxyl group is replaced by an oxo group, and 11-deoxy-11-methylene PGD2, in which the 11-oxo group is replaced by a CH2 group, have little or no DP1 or DP2 agonist activity. However, the 11-methylene analog is a DP2 antagonist (IC50, approximately 2 microM). We conclude that 15R-PGD2, which may be generated by oxidative stress, is a potent and selective DP2 agonist and that modification of the 11-oxo group of PGD2 can result in DP2 antagonist activity.

Authors+Show Affiliations

Meakins-Christie Laboratories, Department of Medicine, McGill University, 3626 St. Urbain Street, Montreal, Quebec H2X 2P2, Canada.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, Non-P.H.S.

Language

eng

PubMed ID

17041009

Citation

Cossette, Chantal, et al. "Agonist and Antagonist Effects of 15R-prostaglandin (PG) D2 and 11-methylene-PGD2 On Human Eosinophils and Basophils." The Journal of Pharmacology and Experimental Therapeutics, vol. 320, no. 1, 2007, pp. 173-9.
Cossette C, Walsh SE, Kim S, et al. Agonist and antagonist effects of 15R-prostaglandin (PG) D2 and 11-methylene-PGD2 on human eosinophils and basophils. J Pharmacol Exp Ther. 2007;320(1):173-9.
Cossette, C., Walsh, S. E., Kim, S., Lee, G. J., Lawson, J. A., Bellone, S., Rokach, J., & Powell, W. S. (2007). Agonist and antagonist effects of 15R-prostaglandin (PG) D2 and 11-methylene-PGD2 on human eosinophils and basophils. The Journal of Pharmacology and Experimental Therapeutics, 320(1), 173-9.
Cossette C, et al. Agonist and Antagonist Effects of 15R-prostaglandin (PG) D2 and 11-methylene-PGD2 On Human Eosinophils and Basophils. J Pharmacol Exp Ther. 2007;320(1):173-9. PubMed PMID: 17041009.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Agonist and antagonist effects of 15R-prostaglandin (PG) D2 and 11-methylene-PGD2 on human eosinophils and basophils. AU - Cossette,Chantal, AU - Walsh,Sinead E, AU - Kim,Seongjin, AU - Lee,Gue-Jae, AU - Lawson,John A, AU - Bellone,Sophie, AU - Rokach,Joshua, AU - Powell,William S, Y1 - 2006/10/13/ PY - 2006/10/17/pubmed PY - 2007/2/13/medline PY - 2006/10/17/entrez SP - 173 EP - 9 JF - The Journal of pharmacology and experimental therapeutics JO - J Pharmacol Exp Ther VL - 320 IS - 1 N2 - Prostaglandin (PG) D2 acts through both the DP(1) receptor, which is coupled to adenylyl cyclase, and the DP2 receptor (chemoattractant receptor-homologous molecule expressed on Th2 cells), which is present on eosinophils, basophils, and Th2 cells and results in cell activation and migration. The most potent prostanoid DP2 agonist so far reported is 15R-methyl-PGD2, in which the hydroxyl group has the unnatural R configuration. In contrast, the corresponding analog possessing the natural 15S configuration is approximately 75 times less potent. This raised the question of whether the isoprostane 15R-PGD2 might have potent DP2 receptor-mediated biological activity. We therefore chemically synthesized 15R-PGD2 and investigated its biological activity. This compound elicited DP2 receptor-mediated CD11b expression in human basophils and eosinophils and induced actin polymerization and migration in eosinophils with a potency about the same as that of PGD2. In contrast, it had only a weak effect on DP1 receptor-mediated adenylyl cyclase activity in human platelets. We also investigated the effects of modification of the 9-hydroxyl and 11-oxo groups of PGD2. Both PGK2, in which the 9-hydroxyl group is replaced by an oxo group, and 11-deoxy-11-methylene PGD2, in which the 11-oxo group is replaced by a CH2 group, have little or no DP1 or DP2 agonist activity. However, the 11-methylene analog is a DP2 antagonist (IC50, approximately 2 microM). We conclude that 15R-PGD2, which may be generated by oxidative stress, is a potent and selective DP2 agonist and that modification of the 11-oxo group of PGD2 can result in DP2 antagonist activity. SN - 0022-3565 UR - https://www.unboundmedicine.com/medline/citation/17041009/Agonist_and_antagonist_effects_of_15R_prostaglandin__PG__D2_and_11_methylene_PGD2_on_human_eosinophils_and_basophils_ L2 - https://jpet.aspetjournals.org/cgi/pmidlookup?view=long&pmid=17041009 DB - PRIME DP - Unbound Medicine ER -